Margaret K. Callahan, M.D., Ph.D.Chief, Division of Hematology/OncologyAssociate Professor
|
|
Education
Post-Graduate Training
Awards
Degree | Institution | Major |
---|---|---|
B.S. | University of Connecticut | Molecular and Cellular Biology |
M.D. | UConn School of Medicine | Medicine |
Ph.D. | UConn Health | Biomedical Science |
Post-Graduate Training
Training | Institution | Specialty |
---|---|---|
Residency | University of California at San Francisco | Internal Medicine, Molecular Medicine Training Program |
Fellowship | Memorial Sloan Kettering Cancer Center | Medical Oncology |
Awards
Name of Award/Honor | Awarding Organization |
---|---|
Science Translational Medicine Associate Scientific Advisor | Science Translational Medicine |
Oncology Travel Trainee Award | Conquer Cancer Foundation |
Clinical Scholars Research Award, 2011-2012 | Memorial Sloan-Kettering Cancer Center |
Connecticut State Medical Society Award | Connecticut State Medical Society |
Trainee Travel Award | American Society for Clinical Investigation |
Medical Scientist Training Program (MSTP) Trainee, 1999-2007 | National Institutes of Health |
Biotechnology Department Undergraduate Research Award | University of Connecticut |
Dean's List (1994-1998) | University of Connecticut |
New England Scholar, (1994-1998) | University of Connecticut |
- Advanced Melanoma
- Cancer Immunotherapy
- Checkpoint Blockade
- Targeted Inhibitors
- Novel Therapies
- Biomarker Development
- Clinical Trials
Margaret Callahan, chief of the division of Hematology and Oncology in the Neag Cancer Center, is a board-certified medical oncologist specializing in the use of immunotherapies to treat melanoma and other cancers. Her research focuses on understanding how immunotherapies work in patients with the goal of characterizing facets of the human immune system that help or hinder the anti-tumor activity of current and novel agents.
Journal Articles
-
Nivolumab monotherapy or combination with ipilimumab with or without cobimetinib in previously treated patients with pancreatic adenocarcinoma (CheckMate 032).
Journal for immunotherapy of cancer 2024 Feb;12(2):